Bipolar depression is the depressive phase of bipolar I or II disorder. Clinically, the depressive episode itself often looks identical to unipolar depression — same symptoms, same severity, same suffering. The distinction is in the broader longitudinal pattern: a patient with bipolar depression has had (or will have) at least one manic or hypomanic episode in addition.
Why does this distinction matter? Because antidepressants alone can destabilize bipolar disorder. Starting an SSRI or SNRI in a patient with bipolar depression can trigger a switch to mania or hypomania (within days to weeks), induce rapid cycling (more than four mood episodes per year), or worsen the long-term trajectory. The medication that helps unipolar depression can hurt bipolar depression when used without mood stabilizer coverage.
Recognizing bipolar depression before treatment begins is one of the most important diagnostic moves in psychiatry. Features that should raise suspicion: family history of bipolar (especially first-degree relatives), early age of first depressive episode (typically teens or early 20s), more frequent but shorter depressive episodes, atypical features (hypersomnia, hyperphagia, leaden paralysis), postpartum psychosis history, treatment-emergent mania or hypomania on prior antidepressants, mixed features within a depressive episode (depressed mood with concurrent racing thoughts, agitation, decreased sleep need).
First-line treatment: a mood stabilizer (lithium, lamotrigine — particularly for depression-predominant patients, valproate) or a second-generation antipsychotic with FDA indication for bipolar depression (quetiapine, lurasidone, cariprazine, olanzapine-fluoxetine combination). Lamotrigine is particularly useful for chronic or prophylactic mood stabilization in depression-predominant bipolar II — it requires slow titration to avoid Stevens-Johnson syndrome risk.
Antidepressants in bipolar depression are controversial. Adding an antidepressant to a mood stabilizer may help some patients, but the evidence is mixed and switching risk persists. Recent guidelines advise caution: prioritize mood stabilizer optimization first, add antidepressant only if needed, monitor closely for switching, taper antidepressant once depression remits rather than continuing indefinitely.
Ketamine and ECT in bipolar depression: ketamine has growing evidence for bipolar depression though switching risk requires monitoring. ECT remains highly effective for severe bipolar depression including with psychotic features. Both should be considered for treatment-resistant cases or where rapid response is needed (severe suicidality, psychosis, catatonia).
When you next see a patient with a major depressive episode, your most consequential clinical move is to screen for bipolar disorder before initiating treatment. Family history, careful history of past mood states, validated screening tools (MDQ, HCL-32). The discrimination matters because it changes treatment direction in ways that affect long-term trajectory.